Biogen Idec Starts Lymphoma Study
Posted on: Thursday, 25 January 2007, 15:00 CST
Biogen Idec has initiated a phase III study of an investigational anti-CD80 monoclonal antibody, galiximab, for patients with lymphoma.
The trial will compare treatment with galiximab in combination with rituximab (Genentech/Biogen Idec's Rituxan), to rituximab in combination with placebo in patients with follicular non-Hodgkin's lymphoma (NHL) that has relapsed or failed to respond to initial therapy.
The primary study objective is to compare the clinical benefit of each treatment arm in subjects with relapsed or refractory, follicular NHL. Progression-free survival is the primary study endpoint.
Because the CD80 target is found uniformly on Reed-Sternberg cells, the malignant component of Hodgkin's disease, as well as the majority of non-Hodgkin's lymphomas, the company will explore expanded proof-of-concept clinical trials, which will begin in 2007, for other indications.
"The safety profile of galiximab in the early studies, along with its hypothesized novel mechanism with Rituxan, suggests the potential for a new era of combination antibody therapies as treatments for lymphoma," said David Parkinson, senior vice president, Oncology Research and Development, Biogen Idec.
Source: Datamonitor
Related Articles
- Pharmasset Reports Positive Results From Phase I HCV Combination Therapy Study
- Tracon Initiates Dosing in Phase I Cancer Combination Therapy Study
- Data From Phase II Clinical Trial of Galiximab in Combination With Rituximab in Patients With Previously Untreated Follicular Lymphoma Presented at International Conference on Malignant Lymphoma
- Romark Completes Enrollment in Phase II Hepatitis Combination Therapy Study
- Medarex Reports Interim Data From Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
- Pharmion and MethylGene Start Phase II Lymphoma Combination Trial
- Rigel Announces Start of Phase 1 Combination Therapy Study of R763/AS703569 in Advanced Malignancies
- ArQule Says Combination Cancer Study Encouraging
- MacroGenics' Novel Monoclonal Antibody Shows Potent Anti-Tumor Activity Against B-Cell Lymphoma in Preclinical Studies
- Market for Lymphoma - The Two Main Groups of Lymphoma in Humans Are Hodgkin's Disease (Characterized By the Growth of Reed-Sternberg Cells) and the Non-Hodgkin's Lymphoma (NHL)
 |
 |
User Comments (0)
RSS Feeds